138 related articles for article (PubMed ID: 25116108)
1. FcγRIIB as a key determinant of agonistic antibody efficacy.
White AL; Beers SA; Cragg MS
Curr Top Microbiol Immunol; 2014; 382():355-72. PubMed ID: 25116108
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.
Williams EL; Tutt AL; Beers SA; French RR; Chan CH; Cox KL; Roghanian A; Penfold CA; Butts CL; Boross P; Verbeek JS; Cragg MS; Glennie MJ
J Immunol; 2013 Oct; 191(8):4130-40. PubMed ID: 24026082
[TBL] [Abstract][Full Text] [Related]
3. FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.
Simpson AP; Roghanian A; Oldham RJ; Chan HTC; Penfold CA; Kim HJ; Inzhelevskaya T; Mockridge CI; Cox KL; Bogdanov YD; James S; Tutt AL; Rycroft D; Morley P; Dahal LN; Teige I; Frendeus B; Beers SA; Cragg MS
Cell Rep; 2022 Jul; 40(3):111099. PubMed ID: 35858562
[TBL] [Abstract][Full Text] [Related]
4. Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.
Vaughan AT; Chan CH; Klein C; Glennie MJ; Beers SA; Cragg MS
J Biol Chem; 2015 Feb; 290(9):5424-37. PubMed ID: 25568316
[TBL] [Abstract][Full Text] [Related]
5. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
White AL; Chan HT; French RR; Beers SA; Cragg MS; Johnson PW; Glennie MJ
Cancer Immunol Immunother; 2013 May; 62(5):941-8. PubMed ID: 23543215
[TBL] [Abstract][Full Text] [Related]
6. Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).
Williams EL; Tutt AL; French RR; Chan HT; Lau B; Penfold CA; Mockridge CI; Roghanian A; Cox KL; Verbeek JS; Glennie MJ; Cragg MS
Eur J Immunol; 2012 Aug; 42(8):2109-20. PubMed ID: 22760702
[TBL] [Abstract][Full Text] [Related]
7. Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity.
Chenoweth AM; Esparon S; Wines BD; Schuurman J; Labrijn AF; Hogarth PM
Immunol Cell Biol; 2023 Aug; 101(7):657-662. PubMed ID: 36997299
[TBL] [Abstract][Full Text] [Related]
8. New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcγRIIB (CD32B).
Roghanian A; Stopforth RJ; Dahal LN; Cragg MS
J Leukoc Biol; 2018 Feb; ():. PubMed ID: 29406570
[TBL] [Abstract][Full Text] [Related]
9. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.
Veri MC; Gorlatov S; Li H; Burke S; Johnson S; Stavenhagen J; Stein KE; Bonvini E; Koenig S
Immunology; 2007 Jul; 121(3):392-404. PubMed ID: 17386079
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.
Stopforth RJ; Cleary KL; Cragg MS
J Clin Immunol; 2016 May; 36 Suppl 1():88-94. PubMed ID: 26922075
[TBL] [Abstract][Full Text] [Related]
12. Testing the role of the FcγRIIB immunoreceptor tyrosine-based inhibitory motif in regulation of the B cell immune response.
Vuyyuru R; Shen S; Manser T
Immun Inflamm Dis; 2015 Sep; 3(3):247-64. PubMed ID: 26417440
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Dahan R; Barnhart BC; Li F; Yamniuk AP; Korman AJ; Ravetch JV
Cancer Cell; 2016 Jun; 29(6):820-831. PubMed ID: 27265505
[TBL] [Abstract][Full Text] [Related]
14. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.
White AL; Chan HT; Roghanian A; French RR; Mockridge CI; Tutt AL; Dixon SV; Ajona D; Verbeek JS; Al-Shamkhani A; Cragg MS; Beers SA; Glennie MJ
J Immunol; 2011 Aug; 187(4):1754-63. PubMed ID: 21742972
[TBL] [Abstract][Full Text] [Related]
15. HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.
Hussain K; Liu R; Smith RCG; Müller KTJ; Ghorbani M; Macari S; Cleary KLS; Oldham RJ; Foxall RB; James S; Booth SG; Murray T; Dahal LN; Hargreaves CE; Kemp RS; Longley J; Douglas J; Markham H; Chee SJ; Stopforth RJ; Roghanian A; Carter MJ; Ottensmeier CH; Frendéus B; Cutress RI; French RR; Glennie MJ; Strefford JC; Thirdborough SM; Beers SA; Cragg MS
J Exp Clin Cancer Res; 2022 Apr; 41(1):131. PubMed ID: 35392965
[TBL] [Abstract][Full Text] [Related]
16. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
17. Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.
Roghanian A; Teige I; Mårtensson L; Cox KL; Kovacek M; Ljungars A; Mattson J; Sundberg A; Vaughan AT; Shah V; Smyth NR; Sheth B; Chan HT; Li ZC; Williams EL; Manfredi G; Oldham RJ; Mockridge CI; James SA; Dahal LN; Hussain K; Nilsson B; Verbeek JS; Juliusson G; Hansson M; Jerkeman M; Johnson PW; Davies A; Beers SA; Glennie MJ; Frendéus B; Cragg MS
Cancer Cell; 2015 Apr; 27(4):473-88. PubMed ID: 25873171
[TBL] [Abstract][Full Text] [Related]
18. A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling.
Li X; Wu J; Carter RH; Edberg JC; Su K; Cooper GS; Kimberly RP
Arthritis Rheum; 2003 Nov; 48(11):3242-52. PubMed ID: 14613290
[TBL] [Abstract][Full Text] [Related]
19. Preclinical in vitro evaluation of immune suppression induced by GYM329, Fc-engineered sweeping antibody.
Iwata Y; Katada H; Okuda M; Doi Y; Ching TJ; Harada A; Takeiri A; Honda M; Mishima M
J Toxicol Sci; 2023; 48(7):399-409. PubMed ID: 37394653
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel Igβ and FcγRIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus.
Kitanaga Y; Yamajuku D; Kubo S; Nakamura K; Maeda M; Seki M; Kaneko Y; Kinugasa F; Morokata T; Kondo Y; Yoshinari H; Nakayamada S; Sumida T; Tanaka Y
Int Immunopharmacol; 2021 Dec; 101(Pt B):108343. PubMed ID: 34781122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
